SPORANOX Oral Solution is indicated: - for the treatment of oral and/or oesophageal candidosis in HIV-positive or other immunocompromised patients. - as prophylaxis of deep fungal infections anticipated to be susceptible to itraconazole, when standard therapy is considered inappropriate, in patients with haematological malignancy or undergoing bone marrow transplant, and who are expected to become neutropenic (i.e. < 500 cells/µL). At present, there are insufficient clinical efficacy data in the prevention of aspergillosis. Consideration should be given to national and/or local guidance regarding the appropriate use of antifungal agents.
Medtronic plc, announced positive clinical trial safety and efficacy results for Sphere-360 , an investigational single-shot mapping and ablation catheter using pulsed field (PF) energy, for treatment of patients with paroxysmal atrial fibrillation (AFib)
Roche announced the launch of the cobas pulse system in select countries accepting the CE Mark. The cobas pulse system marks Roche Diagnostics’ newest generation of connected point of care solutions for professional blood glucose management.
Xtreem Pulse has announced that the PureFlow System has received 510(K) clearance from the FDA for chronic stable angina that...
Allergan Aesthetics, an AbbVie company and Soliton announced a definitive agreement under which Allergan Aesthetics will acquire Soliton and Resonic, its Rapid Acoustic Pulse device which recently received FDA 510(k) clearance and is a non-invasive treatment for the short-term improvement in the appearance of cellulite.